- Home
- UPB vs TYRA Comparison
UPB vs TYRA Comparison
Compare UPB & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPB
- TYRA
- Stock Information
- Founded
- UPB 2021
- TYRA 2018
- Country
- UPB United States
- TYRA United States
- Employees
- UPB N/A
- TYRA N/A
- Industry
- UPB
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- UPB
- TYRA Health Care
- Exchange
- UPB NYSE
- TYRA Nasdaq
- Market Cap
- UPB 521.3M
- TYRA 576.6M
- IPO Year
- UPB 2024
- TYRA 2021
- Fundamental
- Price
- UPB $10.84
- TYRA $9.65
- Analyst Decision
- UPB Strong Buy
- TYRA Strong Buy
- Analyst Count
- UPB 4
- TYRA 7
- Target Price
- UPB $56.50
- TYRA $30.86
- AVG Volume (30 Days)
- UPB 405.0K
- TYRA 292.0K
- Earning Date
- UPB 05-06-2025
- TYRA 05-08-2025
- Dividend Yield
- UPB N/A
- TYRA N/A
- EPS Growth
- UPB N/A
- TYRA N/A
- EPS
- UPB N/A
- TYRA N/A
- Revenue
- UPB $2,296,000.00
- TYRA N/A
- Revenue This Year
- UPB N/A
- TYRA N/A
- Revenue Next Year
- UPB N/A
- TYRA N/A
- P/E Ratio
- UPB N/A
- TYRA N/A
- Revenue Growth
- UPB N/A
- TYRA N/A
- 52 Week Low
- UPB $5.14
- TYRA $6.42
- 52 Week High
- UPB $29.46
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- UPB N/A
- TYRA 50.64
- Support Level
- UPB N/A
- TYRA $8.88
- Resistance Level
- UPB N/A
- TYRA $9.68
- Average True Range (ATR)
- UPB 0.00
- TYRA 0.64
- MACD
- UPB 0.00
- TYRA -0.03
- Stochastic Oscillator
- UPB 0.00
- TYRA 47.62
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.